Repligen Corp (RGEN) Actualités

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the...

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company...

Repligen Launches the CTech™ SoloVPE® PLUS System

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company...

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors PR Newswire BOTHELL, Wash., Dec. 16, 2024...

Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company...

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]